Total Valuation
Nektar Therapeutics has a market cap or net worth of CHF1.93B. The enterprise value is CHF1.35K.
Market CapCHF1.93B
Enterprise ValueCHF1.35K
Share Statistics
Nektar Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders2.98%
Owned by Institutions0.69%
Financial Efficiency
Nektar Therapeutics’s return on equity (ROE) is -1.83 and return on invested capital (ROIC) is -52.82%.
Return on Equity (ROE)-1.83
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-52.82%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee876.70K
Profits Per Employee-2.60M
Employee Count63
Asset Turnover0.20
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nektar Therapeutics is ―. Nektar Therapeutics’s PEG ratio is -0.36.
PE Ratio―
PS Ratio12.91
PB Ratio7.94
Price to Fair Value7.94
Price to FCF-3.42
Price to Operating Cash Flow-8.58
PEG Ratio-0.36
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 55.23M and earned -164.08M in profits. Earnings per share was -9.73.
Revenue55.23M
Gross Profit55.23M
Operating Income-130.77M
Pretax Income-164.21M
Net Income-164.08M
EBITDA-137.00M
Earnings Per Share (EPS)-9.73
Cash Flow
In the last 12 months, operating cash flow was -203.76M and capital expenditures -187.00K, giving a free cash flow of -203.94M billion.
Operating Cash Flow-203.76M
Free Cash Flow-203.94M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Nektar Therapeutics upcoming earnings date is Aug 13, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
Nektar Therapeutics as a current ratio of 4.97, with Debt / Equity ratio of 24.89%
Current Ratio4.97
Quick Ratio4.97
Debt to Market Cap0.12
Net Debt to EBITDA-0.98
Interest Coverage Ratio-4.99
Taxes
In the past 12 months, Nektar Therapeutics has paid -138.00K in taxes.
Income Tax-138.00K
Effective Tax Rate<0.01
Enterprise Valuation
Nektar Therapeutics EV to EBITDA ratio is -6.18, with an EV/FCF ratio of -4.06.
EV to Sales15.34
EV to EBITDA-6.18
EV to Free Cash Flow-4.06
EV to Operating Cash Flow-4.06
Balance Sheet
Nektar Therapeutics has CHF568.60M in cash and marketable securities with CHF143.43M in debt, giving a net cash position of CHF425.17M billion.
Cash & Marketable SecuritiesCHF568.60M
Total DebtCHF143.43M
Net CashCHF425.17M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF5.32
Margins
Gross margin is 99.38%, with operating margin of -236.77%, and net profit margin of -297.07%.
Gross Margin99.38%
Operating Margin-236.77%
Pretax Margin-297.32%
Net Profit Margin-297.07%
EBITDA Margin-248.05%
EBIT Margin-249.91%
Analyst Forecast
The average price target for Nektar Therapeutics is CHF124.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF124.50
Price Target Upside― Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―